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Introduction: This study aimed to validate the utility of the new 
histological classification proposed by the International Association 
for the Study of Lung Cancer (IASLC), American Thoracic Society 
(ATS), and European Respiratory Society (ERS) for identifying the 
prognostic subtypes of adenocarcinomas in Japanese patients; corre-
lations between the classification and the presence of EGFR or KRAS 
mutation status were also investigated.
Methods: We retrospectively reviewed 440 patients with lung 
adenocarcinoma,who underwent resection. The tumors were clas-
sified according to the IASLC/ATS/ERS classification. EGFR and 
KRAS mutations were detected using the established methods.
Results: Five-year disease-free survival rates were: 100% for adeno-
carcinoma in situ (n = 20) and minimally invasive adenocarcinoma 
(n = 33), 93.8% for lepidic-predominant adenocarcinoma (n = 36), 
88.8% for invasive mucinous adenocarcinoma (n = 10), 66.7% for 
papillary-predominant adenocarcinoma (n = 179), 69.7% for acinar-
predominant adenocarcinoma (n = 61), 43.3% for solid-predominant 
adencoarcinoma (n = 78), and 0% for micropapillary-predominant 
adenocarcinoma (n = 19). Multivariate analysis revealed that the new 
classification was an independent predictor of disease-free survival. 
EGFR and KRAS mutations were detected in 90 cases (53.9%) and 
21 cases (13.3%), respectively; EGFR mutations were significantly 
associated with adenocarcinoma in situ, minimally invasive adeno-
carcinoma, lepidic- and papillary-predominant adenocarcinoma, and 
KRAS mutations adenocarcinomas with mucinous tumor subtypes.
Conclusions: We found that the IASLC/ATS/ERS classification 
identified prognostic histologic subtypes of lung adenocarcinomas 
among Japanese patients. Histologic subtyping and molecular testing 
for EGFR and KRAS mutations can help predict patient prognosis 
and select those who require adjuvant chemotherapy.
Key Words: Lung adenocarcinoma, Classification, EGFR, KRAS, 
Prognosis.
(J Thorac Oncol. 2013;8: 52–61)
Lung adenocarcinoma is the most common histologic type of primary lung cancer1,2 and it is a heterogeneous 
tumor from every perspective, including the molecular, clini-
cal, radiological, surgical, and pathological aspects.3 Despite 
the discovery that EGFR mutation is a marker responsive 
to tyrosine kinase inhibitors (TKIs) and is associated with 
improved progression-free survival in patients with advanced 
lung adenocarcinoma,4–7 the 2004 World Health Organization 
(WHO) histologic subclassification of resected lung adeno-
carcinomas has contained great challenges.2 In this context, 
the International Association for the Study of Lung Cancer 
(IASLC), the American Thoracic Society (ATS), and the 
European Respiratory Society (ERS), have proposed a new 
subclassification of lung adenocarcinomas.8 Recently, in a 
surgical series among North American patients, we reported 
that the newly proposed classification of lung adenocarci-
noma correlated with patient outcome.9 A growing number 
of publications from Australia, Germany, and South America 
have validated the new subclassification,10–12 However, there 
are only few reports of this type of validation for the Asian 
population.13
Many studies have shown the prevalence and specificity 
of molecular alterations in lung adenocarcinomas. A helpful 
summary was recently published, describing some of these 
alterations, specifically, the recognized association between the 
frequency of molecular alterations, including EGFR and KRAS 
mutations, and histologic subtypes.8 EGFR mutations, found in 
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approximately 30% of lung adenocarcinomas, are significantly 
associated with nonmucinous adenocarcinomas with a lepidic 
component (formerly nonmucinous bronchioloalveolar 
carcinoma [BAC]) and invasive carcinoma with a lepidic 
component, though EGFR mutations can also be observed 
in tumors with components of papillary and micropapillary 
histologic subtypes.14–20 However, KRAS mutation status, 
present in approximately 10% of lung adenocarcinomas, 
has been shown to be significantly associated with solid and 
invasive mucinous adenocarcinoma subtypes,15,21 but not in all 
studies.16 Herein, whether differences in genetic alterations 
in lung adenocarcinomas correlate with histologic subtypes 
remains controversial.
The aim of the present study was to validate whether 
or not the proposed IASLC/ATS/ERS classification of lung 
adenocarcinomas correlates with patient outcomes in a surgi-
cal series of Japanese patients. In addition, we also investi-
gated the correlation between the proposed IASLC/ATS/ERS 
classification of lung adenocarcinomas and EGFR and KRAS 
mutation status.
PATIENTS AND METHODS
Patients
Between January 2001 and December 2009, 595 con-
secutive patients with lung adenocarcinomas underwent pul-
monary resection at Kyoto University Hospital, Japan. The 
patients were excluded from the present evaluation if they 
had multiple primary lung cancers, underwent chemo- or 
radiotherapy before surgery, underwent incomplete resec-
tion, or had incomplete follow-up data based on the clini-
cal data retrieved from the thoracic surgical database. As a 
result, the present histological investigation included 440 
lung adenocarcinomas, which met the 2004 WHO crite-
ria for primary lung adenocarcinoma.2 Tumor staging was 
performed according to the 7th edition of the tumor, node, 
metastasis classification of the International Union Against 
Cancer.22 This project was approved by the institute’s ethics 
committee.
Histologic Evaluation
All resected specimens were formalin-fixed, sectioned, 
and stained with hematoxylin and eosin, in the conventional 
manner. Small tumors (≤2 cm) were sampled histologically in 
entirety. As needed, mucin stains were performed to evaluate 
for the presence of mucin, and elastic stains were performed to 
evaluate for the presence of pleural or vessel invasions. All the 
histological slides were reviewed by two pathologists (AY, SS) 
who were blinded to patient outcomes. Because interobserver 
discrepancy was diminished before the review was started, 
both pathologists read the previous articles to determine the 
representative patterns of lung adenocarcinoma (lepidic, pap-
illary, micorpapillary, acinar, and solid) and discussed their 
validity.8,9,16 Thereafter, they evaluated for the extent of the 
representative component of lung adenocarcinoma and indi-
vidually determined the predominant histologic pattern. For 
controversial cases, the slides were jointly reviewed under a 
multiheaded microscope and consensus assessment was deter-
mined. The average number of tumor slides reviewed from 
each case was 3.4 (range, 1–33).
All cases were histologically classified according to 
the 2004 WHO classification of lung adenocarcinomas.2 
Thereafter, each tumor was reviewed using comprehensive 
histologic subtyping, recording the percentage in 5% incre-
ments for each histologic component (Fig. 1), according to 
previous methods.9,16 Subsequently, each tumor was classified 
according to the predominant histologic subtype or variant 
in each case, according to the IASLC/ATS/ERS classifica-
tion scheme.8 Tumors were classified as adenocarcinomas in 
situ (AIS), minimally invasive adenocarcinomas (MIA), and 
invasive adenocarcinomas, which were divided into lepidic-
predominant (Lepidic), papillary-predominant (Pap), aci-
nar-predominant (Aci), micropapillary-predominant (MP), 
solid-predominant (Solid), invasive mucinous adenocarcinoma 
FIGURE 1.  Representative histologic 
pattern of lung adenocarcinoma 
(hematoxylin and eosin stains). A, 
Nonmucinous lepidic pattern; this 
area shows the lepidic growth pat-
tern, composed of nonmucinous 
pneumocyte-like cells. B, Papillary 
pattern; this area shows the papillary 
configuration of the tumor gland. 
C, Micropapillary pattern; this area 
shows glandular cells growing in 
small papillary tufts lacking fibrovas-
cular cores within retracted connec-
tive tissue spaceii. D, Acinar pattern; 
this area shows a glandular structure, 
composed of round- to oval-shaped 
glands with desmoplastic reaction. 
E, Solid pattern; this area shows solid 
sheets of tumor cells. F, Mucinous 
lepidic pattern; this area shows the 
lepidic growth pattern, composed of 
goblet-cell like cells with mucin.
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(IMA, formerly mucinous or mixed BAC), and others (includ-
ing colloid adenocarcinoma and fetal adenocarcinoma). Cases 
showing signet-ring cells and clear cell features were found in 
eight tumors and 17 tumors, respectively. Most of these cases 
were included as a component of the solid subtype. Data for 
these cases were recorded, but they were not considered as a 
specific subtype.23,24 The predominant pattern was defined as 
the pattern showing the greatest percentage, not necessarily 
50% or greater.8
The total tumor size was grossly determined and 
recorded, whereas the invasive size was defined by measuring 
only the histologic subtype, not the lepidic growth pattern as 
previously described (Fig. 2).8,9 The size of invasion for each 
case was categorized using the four groups reported by Suzuki 
et al.25: noninvasion group, 1 to 5 mm invasion group, 6 to 
15 mm invasion group, and more than 16 mm invasion group.
Several histologic factors, reported as significant prog-
nostic factors for lung adenocarcinomas, were also investi-
gated. Lymphatic and vascular invasions were deemed to be 
positive when tumor cells were recognized in the lymphatic 
lumen or blood vessel, respectively. Visceral pleural inva-
sion (VPI) was considered to be positive when tumor cells 
extended beyond the elastic layer of the pleura, as determined 
by elastic staining. VPI was classified as PL0, PL1, PL2, and 
PL3, according to the criteria established by International 
Union Against Cancer, 7th edition.22 Tumor grade (well, mod-
erately, and poorly differentiated) was assessed according to 
the 2004 WHO criteria.2
Somatic EGFR and KRAS Mutations
EGFR and KRAS gene mutations were detected by 
previously described methods.19,26 In brief, a section from each 
tumor was frozen immediately after resection. To confirm that 
the section included carcinoma cells, a part of each tumor 
tissue was formalin-fixed, paraffin-embedded, sectioned, and 
observed microscopically. Then, a polymerase chain reaction 
single-strand conformational polymorphism protocol was 
used to detect mutations within exons 18, 19, 20, and 21 of 
the EGFR gene. For screening mutations of the KRAS gene, 
the mutagenic polymerase chain reaction restriction enzyme 
fragment length polymorphism method was used, as described 
in a previous study.27 We sought only codon 12 mutations 
because only mutations in codon 12, and not codon13, of the 
KRAS gene were detected in the report.
Statistics
The impact of the following factors on the overall sur-
vival (OS) and disease-free survival (DFS) rates were evalu-
ated: sex, age, smoking status, surgery type, tumor size, 
pathological stage, tumor grade, lymphatic invasion, vascu-
lar invasion, pleural invasion, EGFR status, KRAS status, and 
size of invasion. These clinicopathological factors were used 
in univariate and multivariate analyses to determine whether 
they had a significant effect on OS and DFS. The survival 
rates were calculated using the Kaplan–Meier method, and the 
differences were analyzed by means of the log-rank test. The 
multivariate analysis was performed by means of the Cox’s 
proportional hazards model. Fisher’s exact tests and χ2 tests 
were used with categorical data. All statistical tests were two-
sided and used a 5% level of significance. Statistical analysis 
was conducted using JMP version 8.0 (SAS Institute, Cary, 
NC).
RESULTS
Clinicopathologic Characteristics
The clinicopathologic characteristics of the patients 
and tumors evaluated in this study are summarized in Table 1. 
The patients were nearly evenly divided between the sexes 
(227 men [51.6%], and 213 women [48.4%]), with a mean 
age of 65.4 years (range, 23–86 years). Of the 425 patients 
with a known smoking status, 190 patients (44.7%) had never 
smoked, 135 patients (31.7%) were former smokers, and 100 
patients (23.5%) were current smokers, with an average smok-
ing index of 55.9 ± 4.1 pack-years. The surgical procedure 
employed in 14 patients (3.2%) was partial resection, in 79 
(17.9%) it was segmentectomy, in 343 (80.0%) it was lobec-
tomy, and in four (0.9%) it was pneumonectomy.
The mean tumor size was 24.3 ± 13.1 mm (range, 
4–92 mm). The most common tumor size observed was less 
than or equal to 20 mm in diameter (n = 214; 48.6%), followed 
by tumors between 21 mm and 30 mm in diameter (n = 118; 
26.8%), 31 to 50 mm in diameter (n = 92; 20.9%), and more 
than 51 mm in diameter (n = 16; 3.6%). Of the tumors with a 
diameter of 20 mm or lesser, only 18 did not indicate invasion, 
whereas 40 tumors had 1 to 5 mm invasions, 116 tumors had 6 
to 15 mm invasions, and 39 tumors had more than 16 mm inva-
sions; of the tumors between 21 mm and 30 mm in diameter, 
two tumors did not indicate invasions and four tumors had 
invasions of 1 to 5 mm. Among the tumors that had diameters 
of more than 31 mm, there were none without invasions or 
with less than 5 mm invasions.
The pathologic stage was IA in 255 patients (58.0%), 
IB in 80 patients (18.2%), IIA in 43 patients (9.8%), IIB in 
11 patients (2.5%), and IIIA in 51 patients (11.6%). Tumor 
FIGURE 2.  This scheme shows how the invasive area in lung 
adenocarcinoma is measured. The central area of the tumor 
shows, basically, a papillary pattern; the lepidic pattern and 
acinar pattern are seen in the peripheral area of this tumor. 
The invasive area was measured in a straight line across the 
largest diameter.
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grades were classified as well, moderately, and poorly 
differentiated in 108 (24.5%), 158 (35.9%), and 174 (39.5%) 
of the cases, respectively. Lymphatic and vascular invasions 
were observed in 72 (16.4%) and 112 (25.4%) of the cases, 
respectively. VPI (PL1, PL2, or PL3) was observed in 100 
cases (22.8%). The 2004 WHO classification and the IASLC/
ATS/ERS classification of lung adenocarcinoma
The proportion of histologic subtypes of lung adeno-
carcinoma according to the 2004 WHO classification and 
the IALSC/ATS/ERS is summarized in Table 2. According 
to the 2004 WHO classification, 88.4% of the cases were 
classified as mixed subtypes, with 20 tumors classified as 
BAC. Of the 20 BAC tumors, only one was a mucinous 
BAC (100% BAC growth pattern tumor composed of muci-
nous tumor cells). Thus, according to the IASLC/ATS/ERS 
classification, 19 tumors (4.5%) and one tumor (0.1%) were 
classified as nonmucinous AIS and mucinous AIS, respec-
tively. There were 332 tumors that were categorized in the 
less than or equal to 3 cm group. Among them, 64 tumors 
without invasion or with invasions of 5 mm or lesser were 
identified. After elimination of 20 AISs, the remaining 44 
cases comprised 36 tumors with the Lepidic pattern and 
eight tumors with the other pattern. Within the group of 36 
tumors, there were two cases with pleural invasion and one 
TABLE 1.  Clinicopathological Characteristics and Five-Year Survival Rate
n % 5-Yr Survival Rate (%) OS (p) DFS (p)
Sex Male 227 51.6 63.1 0.001 0.078
Female 213 48.4 81.3
Age, (yrs) <65 212 48.2 78.6 0.036 0.085
>66 228 51.8 65.7
Smoking status Never 190 44.7 83.6 <0.001 0.068
Former 135 31.7 67.3
Current 100 23.5 54.8
Surgery type Pneumonectomy 4 0.9 0 0.001 <0.001
Lobectomy 343 80 72
Segmentectomy 79 17.9 79.7
Partial resection 14 3.2 58.4
Tumor size (mm) ≤20mm 214 48.6 83 <0.001 <0.001
21–30mm 118 26.8 65.8
31–50mm 92 20.9 65.4
≥51 mm 16 3.6 30.5
Stage IA 255 58 92.7 <0.001 <0.001
IB 80 18.2 74.5
IIA 43 9.8 43.7
IIB 11 2.5 75
IIIA 51 11.6 21.4
Tumor grade Well differentiated 108 24.5 100 <0.001 <0.001
Moderately differentiated 158 35.9 80.1
Poorly differentiated 174 39.5 51
Lymphatic invasion Present 74 16.8 45.2 <0.001 <0.001
Absent 366 83.1 77.7
Vascular invasion Present 112 25.4 43.8 <0.001 <0.001
Absent 328 74.5 82.6
Pleural invasion PL0 340 77.2 78.4 <0.001 <0.001
PL1 53 12 62.1
PL2 33 7.5 52.3
PL3 14 3.1 0
EGFR Mutated 90 53.9 86.7 0.015 0.073
Wild 77 46.1 67.6
KRAS Mutated 21 13.3 70.1 0.349 0.732
Wild 137 86.7 69.9
Size of invasion Noninvasive 20 4.5 100 <0.001 <0.001
1-5mm 44 10 100
6-15 mm 140 31.8 78.9
≥16 mm 236 53.6 59.7
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case with necrosis. Hence 33 MIAs, which included 31 non-
mucinous and two mucinous MIAs, were identified.
The most common histologic subtype among the inva-
sive adenocarcinomas was Pap (n = 179; 40.7%), followed by 
Solid (n = 78; 17.7%), Aci (n = 61; 13.8%), Lepidic (n = 36; 
8.1%), MP (n = 19; 4.3%), IMA (n = 10; 2.2%), and others 
(n = 4; 0.9%). The others included three colloid adenocarcino-
mas and one fetal adenocarcinoma. No enteric adenocarcino-
mas were identified in this study.
EGFR and KRAS Mutation Status
Of the 440 cases, 167 cases were examined for EGFR 
mutations and 158 cases were examined for KRAS mutations, 
and the EGFR and KRAS mutations were mutually exclu-
sive. EGFR mutations were detected in 90 cases (53.9%) 
and mutations within codon 12 of KRAS were observed in 
21 cases (13.3%). The cases with EGFR mutations were 
significantly associated with female patients, patients who 
never smoked, and patients with small tumors (p < 0.001, 
p < 0.001, p = 0.027). However, KRAS mutations were 
significantly associated with former and current smokers 
(p = 0.034). (Table 3)
Figure 3 shows the correlations between the frequency 
of EGFR or KRAS mutations and the proposed IALSC/
ATS/ERS histologic classification. EGFR mutations were 
associated with a high frequency of AIS, MIA, Lepidic, and 
Pap subtypes (frequency: 85.7% AIS, 83.3% MIA, 71.4% 
Lepidic, and 68.5% Pap), followed by Aci (38.4%) and 
MP (40.1%) subtypes, whereas they were uncommon in 
Solid subtype tumors (14.3%) (Fig. 3A). Moreover, EGFR 
mutations were not detected in mucinous subtype tumors, 
including mucinous MIAs and IMAs. However, KRAS 
mutations were detected more often in Aci (23.1%) and 
Solid (25.0%) subtypes, followed by the MIA (8.3%), and 
Pap (4.5%) subtypes (Fig. 3B). No KRAS mutations were 
observed in AIS or Lepidic subtypes, whereas all IMAs (n = 
4) had KRAS mutations.
The IASLC/ATS/ERS classification was also examined 
to determine whether specific tumor features (nonmucinous 
lepidic, mucinous lepidic, papillary, acinar, solid, micropap-
illary) reflected EGFR and KRAS mutation status (data not 
shown). EGFR mutations were more frequently found in the 
adenocarcinomas with nonmucinous lepidic (p < 0.001) and 
papillary (p < 0.001) components than in tumors without 
those components. Conversely, EGFR mutations were less 
frequently found in adenocarcinomas with either mucinous 
lepidic (p < 0.001) or solid (p < 0.001) components than in 
tumors without those components. The most common EGFR 
mutation was in-frame deletions in exon 19 (48 of 90, 53.3%), 
and the second common mutation was missense muta-
tion (L858R) in exon 21 (36 of 90, 40.0%). The correlation 
between the two major EGFR mutations (in-frame deletions in 
exon19 and missense mutations in exon 21) and the presence 
of the six major characteristics, as defined by the IASLC/ATS/
ERS classification, were not distinct. However, KRAS muta-
tions were less frequently found in adenocarcinomas with 
TABLE 2.  Adenocarcinoma Subtypes by IASLC/ATS/ERS and 
2004 WHO Classifications
n %
IASLC/ATS/ERS 
classification
　
AIS(nonmucinous/mucinous) 20 (19/1) 4.5
MIA(nonmucinous/mucinous) 33 (31/2) 7.5
Lepidic 36 8.1
Aci 61 13.8
Pap 179 40.7
Solid 78 17.7
MP 19 4.3
IMA 10 2.2
Others 4 0.9
2004 WHO 
classification
Mixed subtype 389 88.4
BAC(nonmucinous/mucinous) 20 (19/1) 4.5
Acinar 2 0.5
Papillary 7 1.6
Solid with mucin 21 4.8
Others 1 0.2
IASLC, International Association for the Study of Lung Cancer; ATS, American 
Thoracic Society; ERS, European Respiratory Society; WHO, World Health Organiza-
tion; MP, micropapillary-predominant; IMA, invasive mucinous adenocarcinoma; BAC, 
bronchioloalveolar carcinoma; Pap, papillary-predominant; AIS, adenocarcinoma in 
situ; MIA, minimally invasive adenocarcinoma
TABLE 3.  Relationship between Clinicopathological Characteristics and EGFR Mutations/KRAS Mutations
EGFR Mutation EGFR Mutation Detail KRAS Mutation
Mutated Wild pa Exon18 Exon19 Exon20 Exon21 pb Mutated Wild pa
Total 90 77 3 48 3 36 21 137 　
Age, (yr) <65 42 31  0.405 1 26 2 13 0.1 11 57 0.353
>66 48 46 2 22 1 23 10 80
Sex Male 29 45 <0.001 1 18 1 9 0.224 12 59 0.227
Female 61 32 2 30 2 27  9 78
Smoking status Never 59 22 <0.001 1 31 2 25 0.736  6 73 0.034
Former/current 30 51 2 16 1 11 15 64
Tumor size <30mm 74 52  0.027 3 38 3 30 0.630 15 106 0.549
>31mm 16 25 0 10 0  6  6 31 　
aBy χ2 test or Fisher’s exact test.
bComparing difference between Exon19 and Exon21 by χ2 test or Fisher’s exact test.
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nonmucinous lepidic component (p < 0.001) than in tumors 
without this characteristic and were also more frequently 
found in adenocarcinomas with the mucinous lepidic compo-
nent (p < 0.001) than in those without it.
Survival Analysis
Sixty-five patients (14.8%) died as a result of their 
disease and another seven (1.6%) died of other or unknown 
causes during the study follow-up period. The mean clini-
cal follow-up period was 38.3 months (range, 0.4–103 
months). Of the 368 patients (83.6%) alive at the time of 
the analysis, 40 (9.0%) experienced recurrent disease and 
328 (74.5%) had no evidence of disease. Therefore, a total 
of 105 patients either died as a result of their cancer or 
experienced postsurgical recurrence and were included in 
the DFS analysis.
Figure 4A shows the DFS curves, according to IASLC/
ATS/ERS lung adenocarcinoma subtype. AIS and MIA sub-
types were associated with patients with significantly better 
prognoses and a 100% DFS at 5 years. This was followed by 
patients with the Lepidic subtype (5-year DFS rate = 93.8%), 
and the IMA subtype (5-year DFS rate = 88.8%). Solid and 
MP subtypes showed the worst prognoses, with a 43.3% DFS 
at 5 years and a 0% DFS at 3 years, respectively. Aci (5-year 
DFS rate = 69.7%) and Pap (5-year DFS rate = 66.7%) were 
identified as the intermediate survival group between AIS/
MIA/Lepidic/IMA subtypes and Solid/MP subtypes. Figure 
4B shows the overall survival curves, grouped by the IASLC/
ATS/ERS classification of lung adenocarcinomas. None of the 
patients with AIS and MIA subtypes died within the follow-
up period. The patients with the lepidic subtype also showed 
significantly better prognoses with a 5-year OS rate of 100%, 
followed by those with the IMA (5-year OS rate = 88.8%), 
Aci (5-year OS rate = 81.2%), and Pap (5-year OS rate = 
74.7%) subtypes. Solid and MP subtypes were associated with 
patients with the worst prognoses, with a 39.1% OS rate at 5 
years and a 42.0% OS rate at 3 years (the follow-up period did 
not reach 5 years), respectively. However, the OS curves of the 
two subtypes were not clearly separated, compared with their 
DFS curves.
Table 1 also shows the results of the univariate analyses 
of the clinicopathologic factors evaluated in this study. The 
5-year survival rates for the stage IA, IB, IIA, IIB, and IIIA 
groups were 92.7%, 74.5%, 43.7%, 75.0%, and 21.4%, 
respectively, and the differences were statistically significant 
(p < 0.001). Male, aged patients (≤65 years versus > 66 years), 
and former and current smokers (never versus former/current) 
correlated significantly with worse OS (p = 0.001, p = 0.036, 
and p < 0.001, respectively), although, these were not 
significant for DFS. As for the histological parameters, tumor 
grade by the 2004 WHO classification (well differentiated 
versus moderately differentiated versus poorly differentiated), 
lymphatic invasion (present versus absent), vascular invasion 
(present versus absent), and VPI (PL0 versus PL1/2/3) were 
also significant predictors of OS (p < 0.001, p < 0.001, 
p < 0.001, and p < 0.001, respectively). In addition, invasion 
size was also related to DFS; the noninvasion and 1 to 5 mm 
invasion groups showed significantly better prognoses with 
100% DFS at 5 years, compared with the 6 to 15 mm invasion 
group (5-year DFS rate = 78.9%). The group with more than 
16-mm invasion showed the worst prognosis with a 51.7% 
DFS rate at 5 years.
The presence of specific gene mutations also seemed to 
impact OS rates. Patients with tumors having EGFR muta-
tions showed significantly better prognosis, with an 86.7% OS 
rate at 5 years compared with patients with tumors lacking 
the EGFR mutations (5-year OS rate = 67.6%). However, the 
difference in DFS rates between these groups did not reach 
statistically significant levels. The differences in both OS and 
DFS were also not statistically significant between patients 
with mutated KRAS genes and those with the wild type KRAS 
genes.
On the basis of the results of these univariate 
analyses, multivariate analyses were performed using the 
Cox proportional hazards model. As shown in Table 4, the 
FIGURE 3.  Correlations between frequencies of EGFR or 
KRAS mutations and the histologic subtype of the adenocar-
cinomas, based on the IASLC/ATS/ERS classification. A, y axis 
indicates the frequency of EGFR-mutated cases and the x axis 
indicates frequency of lung adenocarcinoma subtypes, based 
on the new IASLC/ATS/ERS classification; (B), y axis indicates 
the frequency of KRAS-mutated cases and the x axis indicates 
the frequency of lung adenocarcinoma subtypes, based on 
the IASLC/ATS/ERS classification. AIS, adenocarcinoma in situ, 
MIA, minimally invasive adenocarcinoma, Lepidic, lepidic pre-
dominant adenocarcinoma, Aci, acinar predominant adeno-
carcinoma, Pap, papillary predominant adenocarcinoma, 
Solid, solid predominant adenocarcinoma, MP, micropapil-
lary predominant adenocarcinoma, IMA, invasive mucinous 
adenocarcinoma; IASLC, International Association for the 
Study of Lung Cancer; ATS, American Thoracic Society; ERS, 
European Respiratory Society.
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multivariate analyses indicated that pathological stage, 
size of invasion, and tumor grade by the IASLC/ATS/ERS 
classification remained significantly associated with DFS; 
patients with stage II or III tumors indicated an increased 
risk for recurrence, compared with those with stage I tumors 
(hazard ratio [HR] = 4.23, 95% confidence interval [CI]: 2.76–
6.55, p < 0.001). Similarly, tumors with invasions of more than 
6 mm also indicated an increased risk of recurrence, compared 
with tumors without invasion or with invasions of 5 mm or 
lesser (HR = 2.00E+5, 95% CI: 2.85–7.2E+165, p = 0.001); 
the high-grade group (Solid/MP/Colloid) also indicated an 
increased risk of recurrence, compared with the low- and 
intermediate-grade groups (AIS/MIA/Lepidic/Aci/Pap/IMA), 
based on the IASLC/ATS/ERS classification. Moreover, the 
pathological stage and the IASLC/ATS/ERS classification 
remained significantly associated with OS; patients with 
stage II or III tumors had increased risks of overall death, 
compared with patients with stage I tumors (HR = 4.82, 95% 
CI: 2.86–8.33, p < 0.001). Moreover, the high-grade group 
had an increased risk of overall death, compared with the low- 
and intermediate-grade groups, based on the IASLC/ATS/
ERS classification (HR = 3.24, 95% CI: 1.79–6.01, p < 0.001).
DISCUSSION
In this study, the proposed IASLC/ATS/ERS histologic 
subtypes of lung adenocarcinomas could predict the prog-
nosis of a patient who underwent surgical resection, and the 
IASLC/ATS/ERS classification would be one of the indepen-
dent parameters for predicting a high risk of recurrence and 
incidence of death by primary lung cancer. Our results almost 
confirm previous studies on predominantly white patients.9–12
Recent advances in diagnostic imaging have enhanced 
the capability for early-stage diagnosis, and histopathologic 
studies have indicated the presence of favorable prognos-
tic subgroups among patients with lung adenocarcinomas. 
FIGURE 4. A, Disease-free sur-
vival curves and (B) overall survival 
curves, for the groups, separated 
by the IASLC/ATS/ERS classifica-
tion of lung adenocarcinomas. 
AIS, adenocarcinoma in situ; MIA, 
minimally invasive adenocarci-
noma; Lepidic, lepidic predomi-
nant adenocarcinoma; Aci, acinar 
predominant adenocarcinoma; Pap, 
papillary predominant adenocar-
cinoma; Solid, solid predominant 
adenocarcinoma; MP, micropapillary 
predominant adenocarcinoma; IMA, 
invasive mucinous adenocarcinoma; 
IASLC, International Association 
for the Study of Lung Cancer; ATS, 
American Thoracic Society; ERS, 
European Respiratory Society.
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Noguchi et al.28 proposed that types A and B tumors, localized 
BAC without and with foci of collapsed alveolar structures, 
were associated with excellent patient prognosis (100% 5-year 
survival). According to the WHO classifications, published in 
1999 and 2004 and which were strongly affected by the report 
by Noguchi et al.,28 BAC was strictly defined as adenocarci-
noma with a pure lepidic growth pattern without stromal, vas-
cular, or pleural invasion. Nonetheless, the term BAC has been 
broadly used, and has included AIS, MIA, and invasive ade-
nocarcinomas with lepidic components.9,10,16,25,29–34 In the new 
proposed IASLC/ATS/ERS classification, the term of BAC 
has been discontinued. At present, AIS and MIA, as per the 
new classification, are tumors that should have 100% 5-year 
DFS, if completely resected.
MIA is a new lung adenocarcinoma subtype defined as a 
small solitary adenocarcinoma (≤3 cm), with a predominantly 
lepidic pattern and invasion of 5 mm or lesser.8 Moreover, the 
IASLC/ERS/ATS classification excludes tumors that invade 
the lymphatics, blood vessels, or pleura, and those that con-
tain necrosis, from the MIA subtype.8 This concept was based 
on only a few studies. In Suzuki’s study25 of 100 lung adeno-
carcinomas measuring 3 cm or lesser, they classified invasion 
according to the size of the fibrotic scar in the tumor. They 
reported 100% 5-year survival for patients with tumors in the 
less than or equal to 5-mm group, 72% 5-year survival for 
tumors in the 6- to 15-mm group, and 57% 5-year survival for 
those that were in the more than 15-mm group. Sakurai et al.31 
also examined 380 peripheral adenocarcinomas of less than 
or equal to 2-cm diameter and found that only 3.3% of the 91 
patients with fibrosis less than or equal to 5 mm had recur-
rence and importantly, 100% were alive at 7 years. Recently, 
Maeshima et al.35 reported that adenocarcinomas comprised 
non-BAC tumors with less than or equal to 5-mm invasive 
area did not exhibit recurrence in their large series. All the 
abovementioned studies were conducted in Japan, raising 
concerns that these findings may not be applicable worldwide. 
However, recently, some studies based in the United States 
have demonstrated increased survival for patients with tumors 
having less than or equal to 5 mm of invasion.9,11,12,29,36 Our 
data with 36 MIAs confirmed that all had 100% 5-year DFS 
and OS, thus supporting the proposed concept and criteria by 
the IASLC/ATS/ERS classification.
There are very limited numbers of reports regarding the 
prognosis for mucinous AIS and mucinous MIA. We identified 
one mucinous AIS and two mucinous MIAs in this study. All 
these tumors were associated with 100% 5-year DFS. The 
mucinous AIS classification can be traced back to the original 
article on BAC by Noguchi et al.,28 where two mucinous cases 
were included. Ichinokawa et al.37 reported that the 5-year DFS 
rate and OS rate for 46 lung adenocarcinomas, predominantly 
composed of goblet cells, were 95.7% and 89.8%, respectively. 
However, we are not certain whether any of these tumors 
would have been classified as AIS or MIA. In this study, no 
pathological details were provided, but it seems that 25 tumors 
may have been classified as mucinous AIS and one as MIA, 
and they may have had a 100% 5-year DFS. Oka et al.38 also 
reported that eight patients with mucinous BACs measuring 
less than 30 mm had a 100% 5-year OS, although pathological 
details were not documented. Our previous report based on an 
American population showed only one patient with mucinous 
MIA, who did not have recurrence.9 Although more data 
are needed to further explore the prognostic significance of 
mucinous AIS and MIA, the two categories are considered 
good prognostic groups, similar to the nonmucinous AIS and 
MIA. Compared with mucinous AIS and mucinous MIA, 
in this study, we found that IMA had an 88.9% 5-year DFS 
rate. IMA is often an aggressive tumor with a multinodular, 
multilobar, and bilateral presentation, and can recur and be 
fatal even when at stage I.36–38 However, the extent to which 
this subtype has malignant potential remains unclear. In the 
present Japanese population-based study, the DFS and OS 
curves for IMA were intermediate between the low-grade 
(AIS/MIA) and high-grade groups (Solid/MP), whereas the 
IMA subtype had a poor prognosis, along with the Solid and 
MP subtypes, in the previous American population-based 
study.9 Conversely, a report from Germany by Warth et al.11 
TABLE 4.  Multivariate Survival Analysis for Disease-Free Survival and Overall Survival
Parameter
DFS OS
Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Surgery type (Lob./Seg./PR vs. pneumonectomy)a 0.46 0.17–1.64 0.211 0.37 0.12–1.39 0.131
Stage (II/III vs. I) 4.23 2.76–6.55 <0.001 4.82 2.86–8.33 <0.001
Tumor grade by 2004 WHO classification (poorly vs.  
well/moderately)
1.35 0.80–2.31 0.255 0.97 0.49–1.92 0.945
Tumor size (>31 mm vs. 1–30 mm) 1.34 0.88–2.03 0.163 1.06 0.63–1.75 0.799
Lymphatic invasion (present vs. absent) 1.1 0.70–1.70 0.645 1.54 0.89–2.60 0.115
Vascular invasion (present vs. absent) 1.45 0.94–2.24 0.089 1.43 0.84–2.41 0.176
Pleural invasion (PL1, PL2, PL3 vs. PL0) 1.27 0.83–1.92 0.248 1.37 0.82–2.26 0.216
Invasion degree (>6 mm vs. 0–5 mm) 2.00E+05 2.851–7.2E+165 0.001 2.83 0.55–51.69 0.245
Tumor grade by IASLC/ATS/ERS classification  
(high vs. low/intermediate)a
1.71 1.06–2.77 0.026 3.24 1.79–6.01 <0.001
aIASLC/ATS/ERS classification (low-grade group: AIS/MIA, intermediate-group: Lepidic/Aci/Pap/IMA, high-grade group: Solid/MP/Colloid).
DFS, disease-free survival; OS, overall survival;CI, confidence interval; Lob, lobectomy; Seg, segmentectomy; PR, partial resection AIS, adenocarcinoma in situ; MIA, 
minimally invasive adenocarcinoma; IASLC, International Association for the Study of Lung Cancer; ATS, American Thoracic Society; ERS, European Respiratory Society; WHO, 
World Health Organization; Solid, solid predominant adenocarcinoma; MP, micropapillary predominant adenocarcinoma.
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showed that IMA had a better prognosis than the bulk of lung 
adenocarcinomas. As for gene alterations, the IMA subtype 
has been shown to harbor none or few EGFR mutations, rather 
favoring KRAS mutations,21,39,40 and are therefore, known to be 
resistant to EGFR-TKIs, and to have no specific treatment.41 
In the present cohort, KRAS mutations were more frequently 
seen in adenocarcinomas with mucinous lepidic components 
than in those without this component. In addition, all IMA 
tumors (4 cases tested) had KRAS mutations detected. To 
consider treatments for this subtype better, a larger cohort 
will need to be studied because of the very low occurrence 
of this subtype among the total number of patients with lung 
adenocarcinomas.
In the present cohort, the most predominant histologic 
subtype was the Pap; patients with the Pap subtype had rela-
tively good survival rates, similar to the Aci subtype, and con-
sistent with the results observed from American and Australian 
patient reports.9,10 However, a study by Warth et al.11 reported 
a worse survival rate for the Pap subtype, possibly the result of 
different ethnic backgrounds, geographical regions, or histo-
logic recognition of the pattern. In addition, the use of EGFR-
TKIs may also be one of the causes for these discrepancies. In 
the current work, the incidence of EGFR mutations was very 
high in the Pap subtype and in the AIS and MIA subtypes, 
which is also supported by previous reports.14–20 In addition, 
these mutations were more frequently observed in adenocar-
cinomas with a papillary component than in those without the 
component. These results indicate that the use of EGFR-TKIs 
for patients with this subtype may influence its prognosis. 
Although tumors with nonmucinous lepidic components are 
strongly associated with EGFR mutations, EGFR-TKIs may 
have a narrow window of opportunity for use for the subtypes 
because most of the subtypes exhibited better prognosis. Thus, 
the prognosis of adenocarcinomas of the Pap subtype require 
further study, after adjusting for the use of EGFR-TKIs.
In the current study, we found that the Solid subtype of 
adenocarcinomas also had a relatively poor prognosis, which 
is consistent with a growing number of studies.,9,42,4311 In addi-
tion, the MP subtype was found to have a poor outcome, in this 
study. The poor prognosis associated with the micropapillary 
pattern confirms observations of multiple previous studies 
and supports the addition of this new subtype to the classifica-
tion scheme.44–48 Interestingly, the 3-year DFS rate for the MP 
subtype was significantly worse than the 3-year DFS for the 
Solid subtype in the present set of data. However, the 3-year 
OS rates were not distinct, similar to the findings of Warth 
et.al.11 The prognostic differentiation between the two sub-
types might be influenced by EGFR status, as the frequency 
of EGFR mutations in the MP subtype was higher than in the 
Solid subtype tumors. Moreover, EGFR mutations were less 
frequently observed in adenocarcinomas with solid compo-
nents than in those without that component, again, as found in 
previous reports.16,17 Therefore, the MP subtype is speculated 
to easily to recur, but to be more susceptible to EGFR-TKIs in 
comparison with the Solid subtype tumors.
In summary, our study indicates that the new IASLC/
ATS/ERS classification identifies histologic subtypes of lung 
adenocarcinomas with prognostic value among Japanese 
patients. Moreover, EGFR mutations were significantly 
identified in AIS/MIA/Lepidic/Pap subtypes. Conversely, 
KRAS mutations were frequently identified in mucinous sub-
types. On the basis of these findings, we believe that histologic 
subtyping and molecular testing for EGFR and KRAS muta-
tions are helpful for predicting prognosis among patients with 
resectable lung cancer and may be helpful in selecting patients 
who require adjuvant chemotherapy.
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